Insulet Corporation

324.34-1.46 (-0.45%)
Oct 28, 4:00:01 PM EDT · NasdaqGS · PODD · USD

Upcoming Earnings

Report date
Nov 6, 2025 (in 8 days)

Key Stats

Market Cap
22.83B
P/E (TTM)
98.58
Basic EPS (TTM)
3.29
Dividend Yield
0%

Recent Filings

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

CEO
Ms. Flavia H. Pease
IPO
5/15/2007
Employees
3,900
Sector
Healthcare
Industry
Medical Devices